13. März 2014 um 8:00 – 14. März 2014 um 17:00
Kardinal Wendel Haus
Mandlstraße 23
80802 München
ab 300 €
CSi Hamburg GmbH
+49 40 307720 97

23. AGAH Annual Meeting 2014

Risk mitigation in early medicines development is the focus of the 2014 Annual Meeting in Munich. Whereas recent meetings mainly addressed aspects of early clinical utility assessment and exploratory development of modern therapies, there is need for an overall evaluation of risks and in consequence for the advancement of mitigation strategies.

A broad range of approaches is offered such as the impact of nonclinical findings, biopharmaceutics, personalised medicine approaches, updates on safety/tolerability from a clinical pharmacology perspective, as well as early investi­­­gation of lack of efficacy. Risk mitigation is increasingly important in early medicines development not only to allow early attrition but also to improve the chances of early drug development.

In Plenary Sessions and Parallel Workshops with much room for discussion the AGAH Annual Meeting 2014 will provide a floor for comprehensive exchange on these topics. As the conference is located in Munich the AGAH has taken the initiative to cooperate with BioM (Biotech Cluster Development GmbH, a nonprofit organisation) in preparing the conference and thereby involve speakers from Munich’s biotechnology sector.

Dr. Kerstin Breithaupt-Grögler 
President AGAH e.V.

Prof. Dr. Hildegard Sourgens 
President Elect AGAH e.V.

Dienstag, 18. Februar 2014, 15.00 Uhr bis ca. 18.00 Uhr

Kardinal Wendel Haus, Katholische Akademie in Bayern, Mandlstraße 23, D-80802 München, Phone: 0 89 / 38 10 2-0

Programm und weitere Informationen


Online Registration

© Copyright 2021 DGPharMed

Wenn Sie noch gar kein Mitglied in der Deutschen Gesellschaft für Pharmazeutische Medizin e.V. sind, hätten wir folgendes Angebot für Sie:

Werden Sie Mitglied und profitieren Sie von einer kostenfreien Mitgliedschaft bis Ende des Jahres.